|
Home » Briefs » Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis

Services

Econ One’s expert economists have experience across a wide variety of services including antitrust, class certification, damages, financial markets and securities, intellectual property, international arbitration, labor and employment, and valuation and financial analysis.

Resources

Econ One’s resources including blogs, cases, news, and more provide a collection of materials from Econ One’s experts.

Cases and Engagements

Get an Inside look at Economics with the experts.
Managing Director
Education

Ph.D. in Economics, University of California, Los Angeles

M.A. in Economics, University of California, Los Angeles

B.S. in Economics, Santa Clara University

Econ One, President, 1997 – Present

Founded Econ One, 1997

Micronomics, Inc., President and CEO, 1994 – 1997

Micronomics, Inc., Executive Vice President, 1988 – 1997

Cofounded Micronomics, Inc., 1988

National Economic Research Associates, Inc. (Last position was Senior Vice President and member of the Board of Directors) 1980 – 1988

U.S. District Court

U.S. Bankruptcy Court

State Court

Federal Energy Regulatory Commission

Various state tax and regulatory commissions

Private arbitration

International Arbitration

Share this Article
September 25, 2015

Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis

Econ One was retained by counsel for the plaintiffs in the case Louisiana Wholesale Drug Co., Inc. v. Sanofi-Aventis. The plaintiffs were a class of direct purchasers of the brand name prescription drug Arava, a treatment for rheumatoid arthritis. They alleged that the defendants violated antitrust laws by improperly delaying the market entry of cheaper generic substitutes to Arava.

Econ One expert Jeffrey Leitzinger submitted an expert report relating to class certification issues. Those issues included the likely impact of a delay in generic competition on the class members, the availability of common, class-wide economic evidence and methodologies that would demonstrate class-wide impact in the form of overcharges, and whether those overcharges could be calculated as a whole on an aggregate basis using reliable methodologies.  The class was certified. Dr. Leitzinger also submitted two expert reports addressing the issues of monopoly power, market definition, and aggregate overcharge damages.  Dr. Leitzinger provided testimony both at deposition and at trial.

Industries: Pharmaceutical

Latest Related Resources and Insights